Literature DB >> 20653669

Warfarin and vitamin K intake in the era of pharmacogenetics.

Yael Lurie1, Ronen Loebstein, Daniel Kurnik, Shlomo Almog, Hillel Halkin.   

Abstract

The considerable variability in the warfarin dose-response relationship between individuals, is explained mainly by genetic variation in its major metabolic (CYP2C9) and target (VKORC1) enzymes. Despite the predominance of pharmacogenetics, environmental factors also affect the pharmacokinetics and pharmacodynamics of warfarin, and are often overlooked. Among these factors, dietary and supplemental vitamin K consumption is a controllable contributor to within-, and between-patient variability of warfarin sensitivity. In this commentary we review the current role of vitamin K in warfarin anticoagulation therapy, with emphasis on the following: 1 The effect of dietary and supplemental vitamin K on warfarin anticoagulation, beyond the impact of genetic variability in CYP2C9 and VKORC1. We deal separately with the effects of vitamin K on warfarin dose requirements during the induction of therapy, as opposed to its effect on stability of anticoagulation control during maintenance therapy. 2 The role of vitamin K supplementation in warfarin treated patients with vitamin K deficiency as well as in patients with unstable warfarin anticoagulation, and 3 The role of therapeutic vitamin K in cases of warfarin over-anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20653669      PMCID: PMC2911546          DOI: 10.1111/j.1365-2125.2010.03672.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  52 in total

Review 1.  Clinical practice. Care of patients receiving long-term anticoagulant therapy.

Authors:  Sam Schulman
Journal:  N Engl J Med       Date:  2003-08-14       Impact factor: 91.245

2.  Interindividual variability in sensitivity to warfarin--Nature or nurture?

Authors:  R Loebstein; H Yonath; D Peleg; S Almog; M Rotenberg; A Lubetsky; J Roitelman; D Harats; H Halkin; D Ezra
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

3.  Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system.

Authors:  Reidar Wallin; David C Sane; Susan M Hutson
Journal:  Thromb Res       Date:  2002-11-25       Impact factor: 3.944

4.  Patient-specific factors predictive of warfarin dosage requirements.

Authors:  Randall K Absher; M Elisabeth Moore; Mary H Parker
Journal:  Ann Pharmacother       Date:  2002-10       Impact factor: 3.154

5.  Multivitamin supplements may affect warfarin anticoagulation in susceptible patients.

Authors:  Daniel Kurnik; Aharon Lubetsky; Ronen Loebstein; Shlomo Almog; Hillel Halkin
Journal:  Ann Pharmacother       Date:  2003-11       Impact factor: 3.154

6.  Dietary phylloquinone depletion and repletion in older women.

Authors:  Sarah L Booth; Ligia Martini; James W Peterson; Edward Saltzman; Gerard E Dallal; Richard J Wood
Journal:  J Nutr       Date:  2003-08       Impact factor: 4.798

7.  Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin.

Authors:  T Khan; H Wynne; P Wood; A Torrance; C Hankey; P Avery; P Kesteven; F Kamali
Journal:  Br J Haematol       Date:  2004-02       Impact factor: 6.998

8.  Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial.

Authors:  Mark A Crowther; James D Douketis; Terri Schnurr; Luigi Steidl; Valentina Mera; Carolina Ultori; Achille Venco; Walter Ageno
Journal:  Ann Intern Med       Date:  2002-08-20       Impact factor: 25.391

9.  Intake and sources of phylloquinone (vitamin K1): variation with socio-demographic and lifestyle factors in a national sample of British elderly people.

Authors:  C W Thane; A A Paul; C J Bates; C Bolton-Smith; A Prentice; M J Shearer
Journal:  Br J Nutr       Date:  2002-06       Impact factor: 3.718

10.  Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients. A prospective, controlled trial.

Authors:  Daniel Kurnik; Ronen Loebstein; Hadas Rabinovitz; Naomi Austerweil; Hillel Halkin; Shlomo Almog
Journal:  Thromb Haemost       Date:  2004-11       Impact factor: 5.249

View more
  18 in total

1.  Herb-drug interaction: The importance of communicating with primary care physicians.

Authors:  Rajarshi Bhadra; Keyvan Ravakhah; Raktim K Ghosh
Journal:  Australas Med J       Date:  2015-10-31

Review 2.  Recommendations to prescribe in complex older adults: results of the CRIteria to assess appropriate Medication use among Elderly complex patients (CRIME) project.

Authors:  Graziano Onder; Francesco Landi; Domenico Fusco; Andrea Corsonello; Matteo Tosato; Miriam Battaglia; Simona Mastropaolo; Silvana Settanni; Manuela Antocicco; Fabrizia Lattanzio
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

Review 3.  Predicting and Understanding the Human Microbiome's Impact on Pharmacology.

Authors:  Reese Hitchings; Libusha Kelly
Journal:  Trends Pharmacol Sci       Date:  2019-06-03       Impact factor: 14.819

4.  Dosage individualization of warfarin using artificial neural networks.

Authors:  Mohammad I Saleh; Sameh Alzubiedi
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

5.  Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction.

Authors:  Daniel Kurnik; Husam Qasim; Sophie Sominsky; Aharon Lubetsky; Noa Markovits; Chun Li; C Michael Stein; Hillel Halkin; Eva Gak; Ronen Loebstein
Journal:  Thromb Haemost       Date:  2012-08-07       Impact factor: 5.249

6.  Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.

Authors:  Ryuhei Saito; Kenji Takeda; Kayo Yamamoto; Akihiko Nakagawa; Hirofumi Aoki; Kosuke Fujibayashi; Minoru Wakasa; Atsushi Motoyama; Mizuho Iwadare; Ryoko Ishida; Nakaba Fujioka; Taketsugu Tsuchiya; Hironobu Akao; Yasuyuki Kawai; Michihiko Kitayama; Kouji Kajinami
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

7.  The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation.

Authors:  Pascal Vranckx; Marco Valgimigli; Hein Heidbuchel
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-03

Review 8.  Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.

Authors:  E Danese; M Montagnana; J A Johnson; A E Rettie; C F Zambon; S A Lubitz; G Suarez-Kurtz; L H Cavallari; L Zhao; M Huang; Y Nakamura; T Mushiroda; M K Kringen; P Borgiani; C Ciccacci; N T Au; T Langaee; V Siguret; M A Loriot; H Sagreiya; R B Altman; M H A Shahin; S A Scott; S I Khalifa; B Chowbay; I M Suriapranata; M Teichert; B H Stricker; M Taljaard; M R Botton; J E Zhang; M Pirmohamed; X Zhang; J F Carlquist; B D Horne; M T M Lee; V Pengo; G C Guidi; P Minuz; C Fava
Journal:  Clin Pharmacol Ther       Date:  2012-11-07       Impact factor: 6.875

9.  Vitamin C deficiency in an anticoagulated patient.

Authors:  George M Yousef; Lynne J Goebel
Journal:  J Gen Intern Med       Date:  2012-11-29       Impact factor: 5.128

10.  Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G<A) gene polymorphisms & their effect on acenocoumarol dose in patients with mechanical heart valve replacement.

Authors:  Anupriya Kaur; Farah Khan; Suraksha S Agrawal; Aditya Kapoor; Surendra K Agarwal; Shubha R Phadke
Journal:  Indian J Med Res       Date:  2013-01       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.